Rocket One's Hoth Therapeutics reports strong HT-001 efficacy results
RKTO•Rocket One said its Hoth Therapeutics unit ended the HT-001 Phase 2a trial early after strong efficacy results and plans to pursue Phase 3. Hoth will seek FDA feedback on advancing the program.
1. Phase 3 plans
Rocket One said its Hoth Therapeutics unit ended the HT-001 Phase 2a trial early after strong efficacy results and plans to pursue a Phase 3 program. Hoth will seek FDA feedback on advancing the treatment for cancer patients.
